Biogen Ups Samsung Bioepis Stake In $700m Bet On Biosimilars

 
• By Jung Won Shin

While Biogen's exercise of its call option in biosimilar joint venture Samsung Bioepis may help further boost the biosimilar company's global presence and leadership in the sector, the focus in South Korea is more on how the change may affect the outcome of an ongoing accounting inspection at Samsung BioLogics, Samsung Bioepis' biggest shareholder.

Call option
Biogen exercises call option in Samsung Bioepis • Source: Shutterstock

More from Business

More from Generics Bulletin